Bluejay Diagnostics, Inc. 8-K Filing

Filing Documents

• ea0271231-8k_bluejay.htm (8-K) — 26KB
• ea027123101ex99-1_bluejay.htm (EX-99.1) — 10KB
• image_001.jpg (GRAPHIC) — 5KB
• ex99-1_001.jpg (GRAPHIC) — 3KB
• 0001213900-25-126358.txt ( ) — 214KB
• bjdx-20251229.xsd (EX-101.SCH) — 3KB
• bjdx-20251229_lab.xml (EX-101.LAB) — 33KB
• bjdx-20251229_pre.xml (EX-101.PRE) — 22KB
• ea0271231-8k_bluejay_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 29, 2025, Bluejay Diagnostics, Inc. issued a press release providing an update regarding the status of its commercial-scale IL-6 antibody production. A copy of that press release is furnished with this report as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated December 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Date: December 30, 2025 2